Navigation Links
MabThera Significantly Extends Survival And Cures More Patients,With Aggressive Lymphoma Than Chemotherapy Alone

Seven year follow up of pivotal trial confirms that more patients are alive today due to MabThera

BASEL, Switzerland, June 4, 2007-A follow-up analysis tracking the outcome of patients with aggressive non-Hodgkin's lymphoma (NHL) who were treated with the innovative cancer therapy MabThera (rituximab) over seven years ago has revealed exciting results (1).

This analysis of the original pivotal phase III study has shown that over half (53%) of the patients treated with MabThera were still alive after seven years compared with just over a third (36%) of patients who had received chemotherapy alone. This means that for every 100 patients with aggressive NHL, 17 more patients would be alive at seven years due to MabThera.

The analysis also demonstrated that more MabThera treated patients were in remission at seven years compared to chemotherapy alone, 52% vs. 29%. As remissions of greater than 5 years are generally considered to be a cure, this study clearly demonstrates that the addition of MabThera to treatment cures more patients with aggressive lymphoma than chemotherapy alone. These benefits are irrespective of age and are seen even in patients with high risk characteristics.

This study outcome, presented at the American Society of Clinical Oncology meeting in Chicago, highlights the impressive impact that MabThera is having on aggressive NHL, a disease in which it has already saved thousands of lives.

"This long-term analysis clearly demonstrates the benefits that MabThera, in combination with chemotherapy, provides to patients with aggressive lymphoma," commented Prof. Bertrand Coiffier, from the Centre Hospitalier Lyon-Sud, a primary investigator of the study. "Furthermore, the results confirm that the addition of MabThera to treatment is critical even for older patients as the benefits were seen in all age groups."

"MabThera continues to prolong and rebuild life for patie
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Innovative Cancer Drug MabThera Again Shown To Improve Survival Rates In Patients With Lymphoma
2. MabThera Significantly Increases Survival of Lymphoma Patients Regardless of Chemotherapy Regimen
3. Arterial Plaque Significantly Reduced in Women Age 50-59 Taking Hormones, Says New Analysis of Womens Health Initiative Data
4. Prexige Study Shows Significantly Less Impact on Blood Pressure Than Ibuprofen in Osteoarthritis Patients with Controlled Hypertension
5. Lumiracoxib Study Showed Significantly Less Impact on Blood Pressure Than Ibuprofen in Osteoarthritis Patients with Controlled Hypertension
6. Actemra (tocilizumab) Significantly Improves Symptoms of Rheumatoid Arthritis Compared to a Current Standard of Care
7. Next Safety, Inc.s Innovative Drug Delivery System Will Replace Cigarettes and Significantly Advance Pulmonary Medication Delivery
8. Ivivis PEMF Technology Significantly Improves Neuron Survival in Parkinsons Disease Model, Study Finds
9. Mercks Investigational Migraine Treatment MK-0974 Significantly Improved Migraine Pain on Several Efficacy Measures in a Phase II Study
10. The Eloxatin-Based Regimen (FOLFOX4) Significantly Improved Progression Free Survival When Given Before and After Surgery in Patients With Resectable Liver Metastases From Colorectal Cancer
11. Nexavar Significantly Extends Overall Survival by 44% in Liver Cancer Patients
Post Your Comments:
(Date:3/18/2010)... March 18 Poniard Pharmaceuticals, Inc. ... innovative oncology therapies, today announced that the U.S. Patent ... the composition of matter patent for picoplatin as RE41209, ... 2010 . The reissue was applied for May ... , the USPTO released the "Issue Notification" for the ...
(Date:3/18/2010)... , March 18 ... Chief Executive Officer, Pfizer, was elected board ... of America (PhRMA) today at the trade ... Chief Executive Officer Christopher Viehbacher ... Directors, and John C. Lechleiter , ...
(Date:3/18/2010)... results in too much ammonia in the blood. , ... , , ... ... (Logo: ... ...
Breaking Medicine Technology:U.S. Patent and Trademark Office Grants Reissue Patent on Picoplatin Composition of Matter 2U.S. Patent and Trademark Office Grants Reissue Patent on Picoplatin Composition of Matter 3U.S. Patent and Trademark Office Grants Reissue Patent on Picoplatin Composition of Matter 4U.S. Patent and Trademark Office Grants Reissue Patent on Picoplatin Composition of Matter 5Pfizer's Jeffrey Kindler Becomes PhRMA Board Chairman; Christopher Viehbacher, John Lechleiter Assume New Posts 2Pfizer's Jeffrey Kindler Becomes PhRMA Board Chairman; Christopher Viehbacher, John Lechleiter Assume New Posts 3Pfizer's Jeffrey Kindler Becomes PhRMA Board Chairman; Christopher Viehbacher, John Lechleiter Assume New Posts 4Pfizer's Jeffrey Kindler Becomes PhRMA Board Chairman; Christopher Viehbacher, John Lechleiter Assume New Posts 5Pfizer's Jeffrey Kindler Becomes PhRMA Board Chairman; Christopher Viehbacher, John Lechleiter Assume New Posts 6Pfizer's Jeffrey Kindler Becomes PhRMA Board Chairman; Christopher Viehbacher, John Lechleiter Assume New Posts 7Pfizer's Jeffrey Kindler Becomes PhRMA Board Chairman; Christopher Viehbacher, John Lechleiter Assume New Posts 8FDA Approves Drug to Treat Condition That Causes Elevated Ammonia Levels 2FDA Approves Drug to Treat Condition That Causes Elevated Ammonia Levels 3FDA Approves Drug to Treat Condition That Causes Elevated Ammonia Levels 4FDA Approves Drug to Treat Condition That Causes Elevated Ammonia Levels 5Johns Hopkins researchers track down protein responsible for chronic rhinosinusitis with polyps 61897 1Johns Hopkins researchers track down protein responsible for chronic rhinosinusitis with polyps 61897 2Johns Hopkins researchers track down protein responsible for chronic rhinosinusitis with polyps 61897 3Exposure to lead tobacco smoke raises risk of ADHD 10856 1Exposure to lead tobacco smoke raises risk of ADHD 10856 2Measuring and modeling blood flow in malaria 61892 1Measuring and modeling blood flow in malaria 61892 2
(Date:3/18/2010)... Taxes, Other Tobacco Prevention Initiatives , ... , , ... ... ... WASHINGTON , March 18 Kids in New Jersey will take center stage in the fight against tobacco on March ...
(Date:3/18/2010)... ... , , ... ... ... New Hampshire will take center stage in the fight against tobacco on March 24 as they join thousands of young people nationwide ...
(Date:3/18/2010)... President and CEO, Legacy(SM) , ... , , ... ... WASHINGTON , March ... ...
(Date:3/18/2010)... of U.S. medical students choosing internal medicine residencies ... significantly impact the shortage of primary care physicians. ... Program report, 2,722 U.S. seniors at medical schools ... 3.4 percent increase from 2,632 in 2009. The ... (2,660), 2007 (2,680), and 2006 (2,668). In comparison, ...
(Date:3/18/2010)... In its 21-year history, under the ... leaders, SRLA has trained more than 40,000 teenagers from ... area to complete the 26.2 mile Los Angeles Marathon. ... volunteer leaders will again participate in the LA Marathon. ... SRLA,s mission is to challenge at-risk secondary students to ...
Breaking Medicine News(10 mins):Health News:New Jersey Kids 'Kick Butts' on March 24 2Health News:New Jersey Kids 'Kick Butts' on March 24 3Health News:New Jersey Kids 'Kick Butts' on March 24 4Health News:New Jersey Kids 'Kick Butts' on March 24 5Health News:New Hampshire Kids 'Kick Butts' on March 24 2Health News:New Hampshire Kids 'Kick Butts' on March 24 3Health News:New Hampshire Kids 'Kick Butts' on March 24 4Health News:Food and Drug Administration Issues Final Rule Regarding Sale, Distribution, and Use of Cigarettes and Smokeless Tobacco 2Health News:Food and Drug Administration Issues Final Rule Regarding Sale, Distribution, and Use of Cigarettes and Smokeless Tobacco 3Health News:Food and Drug Administration Issues Final Rule Regarding Sale, Distribution, and Use of Cigarettes and Smokeless Tobacco 4Health News:Food and Drug Administration Issues Final Rule Regarding Sale, Distribution, and Use of Cigarettes and Smokeless Tobacco 5Health News:Residency match results not encouraging for adults needing primary care 2Health News:Students Run LA Takes 40,000 Students Across the Marathon Finish Line Over Past 21 Years 2Health News:Students Run LA Takes 40,000 Students Across the Marathon Finish Line Over Past 21 Years 3
... Switzerland, March 6 Roche (SWX: ROG.VX; RO.S) announced today ... publicly-held shares of Genentech (NYSE: DNA ) to ... midnight, New York City time, on Friday, March 20, 2009. ... unchanged.Franz B. Humer, Chairman of the Roche Group, said: "Based ...
... incision-free procedure to reverse weight gain after gastric bypass surgery. ... ... 6, 2009 -- NorthShore University HealthSystem (NorthShore) now ... gastric bypass surgery., , , , ,“Revisional Obesity Surgery Endolumenal ...
... Medco listed No. 1 in Health Care: Pharmacy and Other ... people management worldwideFRANKLIN LAKES, N.J., March 6 Medco Health ... 1 position within the Health Care: Pharmacy and Other Services ... In addition, of all companies surveyed globally, Medco was ...
... Mex Veggie Pockets, Falafel Flats and Burrito Bites at Natural ... Dr. Praeger,s Sensible Foods, the leader in sensible, heart-friendly frozen ... all-natural frozen foods. The new products include California ... Pockets, Falafel Flats and Burrito Bites . ...
... pulsed-dye beam with topical meds improved lesions in 1 ... -- Laser therapy can safely and effectively treat mild ... preliminary study of 18 people. , Fourteen of the ... (PDT) using a long-pulsed, pulsed-dye laser and a photosensitizer ...
... The U.S. Consumer Product Safety Commission (CPSC) ... and carbon monoxide (CO) alarm batteries this Sunday ... Time. (Logo: http://www.newscom.com/cgi-bin/prnh/20030904/USCSCLOGO )"Safeguard your family by ... monoxide alarms this weekend," said CPSC,s Acting Chairman ...
Other Medicine News:Health News:Roche Increases Offer Price for Genentech Shares to US$ 93.00 per Share and Extends Offer 2Health News:Roche Increases Offer Price for Genentech Shares to US$ 93.00 per Share and Extends Offer 3Health News:Roche Increases Offer Price for Genentech Shares to US$ 93.00 per Share and Extends Offer 4Health News:NorthShore University HealthSystem Only Hospital in the Region to Use Incisionless Procedure to Reduce Weight Regain 2Health News:NorthShore University HealthSystem Only Hospital in the Region to Use Incisionless Procedure to Reduce Weight Regain 3Health News:Medco Tops Fortune's Lists of 'World's Most Admired' Companies 2Health News:Medco Tops Fortune's Lists of 'World's Most Admired' Companies 3Health News:Dr. Praeger's Sensible Foods Launches Four New Frozen Food Products 2Health News:Dr. Praeger's Sensible Foods Launches Four New Frozen Food Products 3Health News:New Laser Combo Therapy Zaps Acne 2Health News:Replace Smoke and CO Alarm Batteries This Sunday for Daylight Saving Time 2
... primarily by 5-monodeioination of thyroxine (T4) in ... production occurs at a rate which is ... of T3 from the thyroid gland into ... to 80-100 micrograms/day for T4. In addition, ...
... Human Insulin-like growth factor binding protein-3 (IGFBP-3) is ... in postnatal serum, as a component of the ... IGFBP-3, a molecule of IGF-I or IGF-II and ... the actions of the IGFs. The molar concentration ...
... is a monomeric protein produced and stored ... GH is released from the pituitary into ... the regulatory control of hypothalamic somatostatin (SS) ... and frequency of GH release appears to ...
... (GH) is a monomeric protein produced and ... gland. GH is released from the pituitary ... under the regulatory control of hypothalamic somatostatin ... timing and frequency of GH release appears ...
Medicine Products: